Moderna Shares Soar as Pivotal Melanoma Vaccine Trial Meets Key Goals

Moderna and Merck's personalized mRNA cancer vaccine, combined with Keytruda, has met key goals in a pivotal melanoma study. The clinical result sent Moderna shares sharply higher and gave investors their strongest late-stage evidence yet that personalized mRNA treatment can work against cancer.

The Phase 3 trial involved over 1,100 patients with higher-risk or advanced melanoma whose detectable tumors had been completely removed through surgery. The combination significantly extended the period patients lived without their melanoma returning compared to Keytruda alone and reduced the risk of the cancer spreading to distant parts of the body.

The positive result moves Moderna and Merck closer to seeking regulatory approval, but important work remains. The Phase 3 trial is continuing to evaluate additional outcomes, including whether the treatment ultimately improves overall survival. Safety will also remain part of the evaluation, with Merck's Dr. Jane Healy describing the therapy as well tolerated.

The success in melanoma provides late-stage validation for the underlying personalized treatment strategy. Moderna and Merck are already studying the personalized vaccine approach in other tumor types, including non-small cell lung cancer, bladder cancer, and renal cell carcinoma.